Page 55 - TD-2-3

Tumor Discovery CE-SWI in desmoid fibromatosis assessment

3. Wu C, Amini-Nik S, Nadesan P, et al., 2010, Aggressive during active observation: A retrospective cohort study. Ann
fibromatosis (desmoid tumor) is derived from mesenchymal Surg, 271: 748–755.
progenitor cells. Cancer Res, 70(19): 7690–7698.
https://doi.org/10.1097/SLA.0000000000003073
https://doi.org/10.1158/0008-5472.CAN-10-1656
15. Valenzuela RF, Madewell JE, Kundra V, et al., 2021, Advanced
4. Li M, Cordon-Cardo C, Gerald WL, et al., 1996, Desmoid imaging in musculoskeletal oncology: Moving away from
fibromatosis is a clonal process. Hum Pathol, 27(9): 939–943. RECIST and embracing advanced bone and soft tissue
https://doi.org/10.1016/s0046-8177(96)90221-x tumor imaging (ABASTI)-part II-novel functional imaging
techniques. Semin Ultrasound CT MR, 42(2): 215–227.
5. Cadour F, Tradi F, Bartoli A, et al., 2023, Diffusion weighted
imaging changes in extra-abdominal desmoid tumor after https://doi.org/10.1053/j.sult.2020.08.013
cryotherapy. Ann Med, 55(1): 521–525. 16. Haacke EM, Reichenbach JR, 2014, Susceptibility Weighted
Imaging in MRI: Basic Concepts and Clinical Applications.
https://doi.org/10.1080/07853890.2023.2174589
Hoboken: John Wiley and Sons.
6. Sheth PJ, Del Moral S, Wilky BA, et al., 2016, Desmoid
fibromatosis: MRI features of response to systemic therapy. 17. Halefoglu AM, Yousem DM, 2018, Susceptibility weighted
Skeletal Radiol, 45: 1365–1373. imaging: Clinical applications and future directions. World J
Radiol, 10(4): 30–45.
https://doi.org/10.1007/s00256-016-2439-y
https://doi.org/10.4329/wjr.v10.i4.30
7. Shinagare AB, Ramaiya NH, Jagannathan JP, et al., 2011,
A to Z of desmoid tumors. AJR Am J Roentgenol, 197(6): 18. Haller S, Haacke EM, Thurnher MM, et al., 2021,
W1008–W1014. Susceptibility-weighted imaging: Technical essentials and
clinical neurologic applications. Radiology, 299(1): 3–26.
https://doi.org/10.2214/AJR.11.6657
https://doi.org/10.1148/radiol.2021203071
8. Sundaram M, McGuire MH, Schajowicz F, 1987, Soft-tissue
masses: Histologic basis for decreased signal (short T2) 19. Skalski KA, Kessler AT, Bhatt AA, 2018, Hemorrhagic and
on T2-weighted MR images. AJR Am J Roentgenol, 148(6): non-hemorrhagic causes of signal loss on susceptibility-
1247–1250. weighted imaging. Emerg Radiol, 25: 691–701.
https://doi.org/10.2214/ajr.148.6.1247 https://doi.org/10.1007/s10140-018-1634-7
9. Gounder MM, Lefkowitz RA, Keohan ML, et al., 2011, 20. Eisenhauer EA, Therasse P, Bogaerts J, et al., 2009, New
Activity of Sorafenib against desmoid tumor/deep response evaluation criteria in solid tumours: Revised
fibromatosis. Clin Cancer Res, 17(12): 4082–4090. RECIST guideline (version 1.1). Eur J Cancer, 45(2):
228–247.
https://doi.org/10.1158/1078-0432.ccr-10-3322
https://doi.org/10.1016/j.ejca.2008.10.026
10. Zanchetta E, Ciniselli C, Bardelli A, et al., 2021, Magnetic
resonance imaging patterns of tumor response to 21. Therasse P, Arbuck SG, Eisenhauer EA, et al., 2000, New
chemotherapy in desmoid‐type fibromatosis. Cancer Med, guidelines to evaluate the response to treatment in solid
10(13): 4356–4365. tumors. European Organization for Research and Treatment
of Cancer, National Cancer Institute of the United States,
https://doi.org/10.1002/cam4.3973 National Cancer Institute of Canada. J Natl Cancer Inst,
11. Subhawong TK, Feister K, Sweet K, et al., 2021, MRI 92(3): 205–216.
volumetrics and image texture analysis in assessing https://doi.org/10.1093/jnci/92.3.205
systemic treatment response in extra-abdominal desmoid
fibromatosis. Radiol Imaging Cancer, 3(4): e210016. 22. Ko CC, Yeh LR, Kuo YT, et al., 2021, Imaging biomarkers for
evaluating tumor response: RECIST and beyond. Biomarker
https://doi.org/10.1148/rycan.2021210016
Res, 9(1): 52.
12. Zhou MY, Bui NQ, Charville GW, et al., 2022, Current https://doi.org/10.1186/s40364-021-00306-8
management and recent progress in desmoid tumors.
Cancer Treat Res Commun, 31: 100562. 23. Koh DM, Collins DJ, 2007, Diffusion-weighted MRI in the
body: Applications and challenges in oncology. AJR Am J
https://doi.org/10.1016/j.ctarc.2022.100562
Roentgenol, 188(6): 1622–1635.
13. Otero S, Moskovic EC, Strauss DC, et al., 2015, Desmoid- https://doi.org/10.2214/AJR.06.1403
type fibromatosis. Clin Radiol, 70(9): 1038–1045.
24. Messiou C, Collins DJ, Morgan VA, et al., 2014, Use of
https://doi.org/10.1016/j.crad.2015.04.015 apparent diffusion coefficient as a response biomarker in
14. Cassidy MR, Lefkowitz RA, Long N, et al., 2020, Association bone: Effect of developing sclerosis on quantified values.
of MRI T2 signal intensity with desmoid tumor progression Skeletal Radiol, 43(2): 205–208.

Volume 2 Issue 3 (2023) 8 https://doi.org/10.36922/td.1414